Monoclonal Antibody Discovery and Analysis Market Report 2022-2032

The Monoclonal Antibody Discovery and Analysis Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Demand for Monoclonal Antibodies for Cancer Treatments

Monoclonal antibodies have demonstrated anticancer efficacy in a variety of cancers, thus they are not necessary for cancer therapy. Most toxicities, including fever, nausea, fatigue, changes in blood pressure, and bronchospasm, are self-limiting. The efficacy and timeliness of antibody-based diagnostic tests for a variety of disorders have both been enhanced by monoclonal antibodies. Clinical studies for more than 250 therapeutic monoclonal antibodies are now being conducted. These antibodies are used to treat cancer, autoimmune disorders, infectious diseases, and transplant patients. Inadequate effector functions, immunogenicity, and problems with pharmacokinetics have all been addressed through chimerization and humanization. As of November 1, 2021, 11 antibody treatments had been given first clearance for usage in either the European Union or the United States: Therapeutic antibodies will unavoidably continue to be a key component of drug research for many years to come. Regardless of the particular path used to produce the next generation of monoclonal antibody therapies, this is true.

What Questions Should You Ask before Buying a Market Research Report?

How is the monoclonal antibody discovery and analysis market evolving?
What is driving and restraining the monoclonal antibody discovery and analysis market?
How will each monoclonal antibody discovery and analysis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
How will the market shares for each monoclonal antibody discovery and analysis submarket develop from 2022 to 2032?
What will be the main driver for the overall market from 2022 to 2032?
Will leading monoclonal antibody discovery and analysis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
Who are the leading players and what are their prospects over the forecast period?
What are the monoclonal antibody discovery and analysis projects for these leading companies?
How will the industry evolve during the period between 2020 and 2032? What are the implications of monoclonal antibody discovery and analysis projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the monoclonal antibody discovery and analysis market?
Where is the monoclonal antibody discovery and analysis market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the monoclonal antibody discovery and analysis market today, and over the next 10 years:

Our 437-page report provides 168 tables and 183 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the monoclonal antibody discovery and analysis market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising monoclonal antibody discovery and analysis prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Business Type

Instruments Manufacturing
Services & Solutions
Ancillary Kits

Application

Therapeutic Antibody Discovery
Critical Reagent Antibody Discovery
Biomarker and Diagnostic Antibody Discovery
Research Antibody Discovery

Platform

Hybridoma
Humanization
Phage Display
Yeast Display
Transgenic Rodents

Type

- Antigen Development

Monoclonal Antibody Discovery
Monoclonal Antibody Manufacturing
Polyclonal Antibodies
Label-free Kinetics Analysis
Cell Banking

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

U.S.
Canada

Europe

Germany
Spain
United Kingdom
France
Italy
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of Asia Pacific

Middle East & Africa

Turkey
Saudi Arabia
South Africa
Rest of Middle East & Africa

Latin America

Brazil
Mexico
Rest of Latin America

The report also includes profiles and for some of the leading companies in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

AbbVie Inc.
Amgen Inc.
Amneal Pharmaceutical LLC
AstraZeneca
Bayer AG
BIOGEN
Bristol- Myers Squibb company
Eisai Co. Ltd
Eli Lilly and Company
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson Ltd.
Lupin Limited
Viatris Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zydus Lifesciences Limited

Overall world revenue for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 in terms of value the market will surpass US$5,610 million in 2022, this work calculates. We predict strong revenue growth through to 2032. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 report help you?

In summary, this 430+ page report provides you with the following knowledge:

Revenue forecasts to 2032 for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 Market, with forecasts for business type, platform, type, application and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Monoclonal Antibody Discovery & Analysis Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Launches of New Products
3.2.1.2 Growing Funding and Healthcare Costs
3.2.2 Market Restraining Factors
3.2.2.1 Price Limits
3.2.2.2 Pressures for Regulatory Approval
3.2.2.3 Induction of Biosimilars
3.2.3 Market Opportunities
3.2.3.1 Pandemic Offered Opportunities
3.2.3.2 Patent Exclusive Rights
3.3 Supply Chain
3.3.1 Immunotherapy Drug Supply Chain and Logistics Challenges
3.3.2 Immunotherapies' Vulnerability
3.3.3 A One-of-a-Kind Starting Point for T-Cell Treatments
3.3.4 The Supply Chain's Missing Manufacturing Link
3.3.5 Limited Availability
3.3.6 Keeping Command of the Immunotherapy Supply Chain
3.4 Cold chain
3.4.1 Agencies Favor Transport Simulation
3.4.2 Packaging Qualification for Thermal
3.4.3 Requests for Information Regarding the Schedule of Verification Studies
3.5 Recent Trends/ Developments
3.5.1 The FDA Received an Investigational New Drug (IND) Application for VRDN-002
3.5.2 Verseau Therapeutics, Inc. Reported on January 4, 2022, FDA Approval
3.5.3 A Veterinary mAb Receives FDA Approval for the First Time
3.5.4 Two Antibody Therapies Are in Seagen's Clinical Study Queue.
3.5.5 Spirea Raises £2.4 Million to Create Cancer-Specific Antibody Drug Conjugates
3.5.6 Exelixis, Inc. of California and BioInvent International AB of Swedenpartner to Create New Antibodies for Immuno-oncology Treatments
3.6 COVID-19 Impact Analysis
3.7 Porter’s Five Forces Analysis
3.7.1 Supplier Power
3.7.2 Buyer Power
3.7.3 Competitive Rivalry
3.7.4 Threat from Substitutes
3.7.5 Threat of New Entrants

4 Monoclonal Antibody Discovery & Analysis Market Analysis by Business Type

4.1 Key Findings
4.2 Business Type Segment: Market Attractiveness Index
4.3 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn)
4.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
4.5 Instruments Manufacturing
4.6 Services & Solutions
4.6.1 Services
4.6.2 Solutions
4.7 Ancillary kits

5 Monoclonal Antibody Discovery & Analysis Market Analysis by Application

5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn)
5.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
5.5 Therapeutic Antibody Discovery
5.5.1 Transgenic Animal Leveraging Transgenic Animal Platforms for Antibody Discovery
5.5.2 Surrogate Antibodies
5.5.3 Drug Development
5.5.4 CAR-T Antibody Development
5.6 Critical Reagent Antibody Discovery
5.6.1 Anti-Idiotype Antibodies
5.6.2 Reagents and Tests for Immunogenicity and ADA
5.6.3 Antibodies and Assays for PK/PD/ADA
5.6.4 Studies for Potency
5.7 Biomarker and Diagnostic Antibody Discovery
5.8 Research Antibody Discovery

6 Monoclonal Antibody Discovery & Analysis Market Analysis by Platform

6.1 Key Findings
6.2 Platform Segment: Market Attractiveness Index
6.3 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn)
6.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
6.5 Hybridoma
6.6 Humanization
6.7 Phage Display
6.8 Yeast display
6.9 Transgenic Rodents

7 Monoclonal Antibody Discovery & Analysis Market Analysis by Type

7.1 Key Findings
7.2 Type Segment: Market Attractiveness Index
7.3 Type Segment Market Attractiveness Index
7.4 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn)
7.5 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
7.6 Antigen Development
7.7 Monoclonal Antibody Discovery
7.8 Monoclonal Antibody Manufacturing
7.9 Polyclonal Antibodies
7.10 Label-Free Kinetics Analysis
7.11 Cell Banking

8 Monoclonal Antibody Discovery & Analysis Market Analysis by Region

8.1 Key Findings
8.2 Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
8.3 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn)
8.4 Monoclonal Antibody Discovery & Analysis Market by Region
8.5 Monoclonal Antibody Discovery & Analysis Market by Business Type
8.6 Monoclonal Antibody Discovery & Analysis Market by Application
8.7 Monoclonal Antibody Discovery & Analysis Market by Platform
8.8 Monoclonal Antibody Discovery & Analysis Market by Type

9 North America Monoclonal Antibody Discovery & Analysis Market Analysis

9.1 Key Findings
9.2 North America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
9.3 North America Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country
9.5 Market Size Estimation and Forecast by Business Type
9.6 Market Size Estimation and Forecast by Application
9.7 Market Size Estimation and Forecast by Platform
9.8 Market Size Estimation and Forecast by Type
9.9 U.S. Market Analysis
9.10 Canada Market Analysis

10 Europe Monoclonal Antibody Discovery & Analysis Market Analysis

10.1 Key Findings
10.2 Europe Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
10.3 Europe Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
10.4 Market Size Estimation and Forecast by Country
10.5 Market Size Estimation and Forecast by Business Type
10.6 Market Size Estimation and Forecast by Application
10.7 Market Size Estimation and Forecast by Platform
10.8 Market Size Estimation and Forecast by Type
10.9 Germany Market Analysis
10.10 UK Market Analysis
10.11 France Market Analysis
10.12 Italy Market Analysis
10.13 Spain Market Analysis
10.14 Rest of Europe Market Analysis

11 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Analysis

11.1 Key Findings
11.2 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
11.3 Asia-Pacific Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
11.4 Market Size Estimation and Forecast by Country
11.5 Market Size Estimation and Forecast by Business Type
11.6 Market Size Estimation and Forecast by Application
11.7 Market Size Estimation and Forecast by Platform
11.8 Market Size Estimation and Forecast by Type
11.9 China Market Analysis
11.10 India Market Analysis
11.11 Japan Market Analysis
11.12 South Korea Market Analysis
11.13 Australia Market Analysis
11.14 Rest of Asia-Pacific Market Analysis

12 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Analysis

12.1 Key Findings
12.2 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
12.3 Middle East and Africa Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country
12.5 Market Size Estimation and Forecast by Business Type
12.6 Market Size Estimation and Forecast by Application
12.7 Market Size Estimation and Forecast by Platform
12.8 Market Size Estimation and Forecast by Type
12.9 South Africa Market Analysis
12.10 Saudi Arabia Market Analysis
12.11 Turkey Market Analysis
12.12 Rest of Middle East and Africa Market Analysis

13 Latin America Monoclonal Antibody Discovery & Analysis Market Analysis

13.1 Key Findings
13.2 Latin America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
13.3 Latin America Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
13.4 Market Size Estimation and Forecast by Country
13.5 Market Size Estimation and Forecast by Business Type
13.6 Market Size Estimation and Forecast by Application
13.7 Market Size Estimation and Forecast by Platform
13.8 Market Size Estimation and Forecast by Type
13.9 Brazil Market Analysis
13.10 Mexico Market Analysis
13.11 Rest of Latin America Market Analysis

14 Competitive Landscape

14.1 Company Share Analysis
14.2 Key Business Strategy Analysis- Acquisition
14.3 Key Business Strategy Analysis- Agreement
14.4 Key Business Strategy Analysis- Alliance
14.5 Key Business Strategy Analysis- Collaboration
14.6 Key Business Strategy Analysis- Expansion
14.7 Key Business Strategy Analysis- Joint Venture
14.8 Key Business Strategy Analysis- New Product Launch
14.9 Key Business Strategy Analysis- Partnership

15 Company Profiles

15.1 AbbVie Inc.
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2017-2021
15.1.3.2 Gross Profit, 2017-2021
15.1.3.3 R&D Expenses, 2017-2021
15.1.3.4 Regional Revenue Share
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Amgen Inc.
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Financial Analysis
15.2.3.1 Net Revenue, 2017-2021
15.2.3.2 Gross Profit, 2017-2021
15.2.3.3 R&D Expenses, 2017-2021
15.2.4 Product Benchmarking
15.2.5 Strategic Outlook
15.3 Amneal Pharmaceutical LLC
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 R&D Expenses, 2017-2021
15.3.4 Strategic Outlook
15.4 AstraZeneca
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2017-2021
15.4.3.2 R&D Expenses, 2017-2021
15.4.3.3 Regional Revenue Share, 2021 (%)
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Bayer AG
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 R&D Expenses, 2017-2021
15.5.3.3 Regional Revenue Share, 2021 (%)
15.5.4 Strategic Outlook
15.6 BIOGEN
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 R&D Expenses, 2017-2021
15.6.3.3 Regional Revenue Share, 2021 (%)
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Bristol- Myers Squibb company
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 R&D Expenses, 2017-2021
15.7.3.3 Regional Revenue Share, 2021 (%)
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 Eisai Co.Ltd
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 R&D Expenses, 2017-2021
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Eli Lilly and Company
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2017-2021
15.9.3.2 R&D Expenses, 2017-2021
15.9.3.3 Regional Revenue Share, 2021 (%)
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 F. Hoffman-La Roche Ltd.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 R&D Expenses, 2017-2021
15.10.3.3 Regional Revenue Share, 2021 (%)
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 GlaxoSmithKline plc
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2018-2021
15.11.3.2 R&D Expenses, 2017-2021
15.11.3.3 Regional Revenue Share
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Johnson & Johnson Ltd
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2017-2021
15.12.3.2 R&D Expenses, 2017-2021
15.12.3.3 Regional Revenue Share, 2021 (%)
15.12.4 Strategic Outlook
15.13 Lupin Limited
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Product Benchmarking
15.13.4 Strategic Outlook
15.14 Viatris Inc.
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2017-2021
15.14.3.2 R&D Expenses, 2017-2021
15.14.4 Product Benchmarking
15.14.5 Strategic Outlook
15.15 Novartis AG
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2017-2021
15.15.3.2 R&D Expenses, 2017-2021
15.15.3.3 Regional Revenue Share, 2021 (%)
15.15.4 Product Benchmarking
15.15.5 Strategic Outlook
15.16 Pfizer Inc.
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2017-2021
15.16.3.2 Regional Revenue Share, 2021 (%)
15.16.4 Strategic Outlook
15.17 Regeneron Pharmaceuticals Inc
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2017-2021
15.17.3.2 R&D Expenses, 2017-2021
15.17.4 Product Benchmarking
15.17.5 Strategic Outlook
15.18 Sanofi S.A.
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2017-2021
15.18.3.2 R&D Expenses, 2017-2021
15.18.3.3 Regional Revenue Share, 2021 (%)
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook
15.19 Teva Pharmaceutical Industries Ltd.
15.19.1 Company Snapshot
15.19.2 Company Overview
15.19.3 Financial Analysis
15.19.3.1 Net Revenue, 2017-2021
15.19.3.2 R&D Expenses, 2017-2021
15.19.3.3 Regional Revenue Share, 2021 (%)
15.19.4 Strategic Outlook
15.20 Zydus Lifesciences Limited
15.20.1 Company Snapshot
15.20.2 Company Overview
15.20.3 Product Benchmarking
15.20.4 Strategic Outlook

16 Conclusion and Recommendations

16.1 Concluding Remarks from
16.2 Recommendations for Market Players

Companies Mentioned

AbbVie Inc.
Amgen Inc.
Amneal Pharmaceutical LLC
AstraZeneca
Bayer AG
BIOGEN
Bristol- Myers Squibb company
Eisai Co. Ltd.
Eli Lilly and Company
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson Ltd.
Lupin Limited
Viatris Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zydus Lifesciences Limited
Abeona Therapeutics
Acucela
Adaptimmune Therapeutics
Autolus
AveXis
BioCancell
Biomay
Biomiga
BioReliance
Biotec Services International
Celladon
Cellectis
Cellular Biomedicine Group
Delphi Genetics
Department of Neuroscience, University of Minnesota
Desktop Genetics
DNAtrix
Elixirgen Scientific
Epeius Biotechnologies
EUFETS
Eurofins Genomics
South American Society of Gene and Cell Therapy
GEG Tech
Genable Technologies
Immune Design
Immune Technology
ImmunoGenes
Immunomic Therapeutics
Inbiomed
VIVEbiotech
Voyager Therapeutics
Waisman Biomanufacturing
Xpress Biologics
Association of British Pharmaceutical Industry (ABPI)
Central Drugs Standard Control Organization (CDSCO)
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
South American Commission
South American Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Indian Drug Manufacturer's Association (IDMA)
International Society of Pharmaceutical Engineering (IPSE)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Pharmaceutical and Medical Devices Agency (PMDA)
World Health Organization (WHO)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4698EUR$5,459USD£3,950GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€5353EUR$6,219USD£4,500GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6542EUR$7,601USD£5,500GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8267EUR$9,605USD£6,950GBP